^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

rezetamig (JNJ-8780)

i
Other names: JNJ-8780, JNJ-75348780
Associations
Company:
J&J
Drug class:
CD3 agonist, CD22 inhibitor
Related drugs:
Associations
17d
New P1 trial • Combination therapy
|
JNJ-8543 • rezetamig (JNJ-8780)
11ms
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
P1, N=148, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Sep 2026 --> May 2025
Trial completion date
|
BCL2 (B-cell CLL/lymphoma 2)
|
rezetamig (JNJ-8780)
11ms
A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer (clinicaltrials.gov)
P1, N=70, Recruiting, Janssen Research & Development, LLC | Not yet recruiting --> Recruiting | Trial completion date: Jul 2028 --> Jul 2026
Enrollment open • Trial completion date • Combination therapy
|
JNJ-8543 • rezetamig (JNJ-8780)
11ms
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
P1, N=148, Active, not recruiting, Janssen Research & Development, LLC | Trial primary completion date: Oct 2023 --> Apr 2025
Trial primary completion date
|
BCL2 (B-cell CLL/lymphoma 2)
|
rezetamig (JNJ-8780)
12ms
New P1 trial • Combination therapy
|
JNJ-8543 • rezetamig (JNJ-8780)
1year
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
P1, N=148, Active, not recruiting, Janssen Research & Development, LLC | Recruiting --> Active, not recruiting
Enrollment closed
|
BCL2 (B-cell CLL/lymphoma 2)
|
rezetamig (JNJ-8780)
1year
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
P1, N=200, Recruiting, Janssen Research & Development, LLC | Trial primary completion date: May 2023 --> Oct 2023
Trial primary completion date
|
BCL2 (B-cell CLL/lymphoma 2)
|
rezetamig (JNJ-8780)
over1year
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
P1, N=200, Recruiting, Janssen Research & Development, LLC | Trial completion date: May 2025 --> Sep 2026
Trial completion date
|
BCL2 (B-cell CLL/lymphoma 2)
|
rezetamig (JNJ-8780)
almost2years
Enrollment change
|
BCL2 (B-cell CLL/lymphoma 2)
|
rezetamig (JNJ-8780)
almost2years
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
P1, N=120, Recruiting, Janssen Research & Development, LLC | Trial completion date: Mar 2024 --> May 2025
Trial completion date
|
BCL2 (B-cell CLL/lymphoma 2)
|
rezetamig (JNJ-8780)
almost3years
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
P1, N=120, Recruiting, Janssen Research & Development, LLC | Trial completion date: May 2023 --> Sep 2023
Trial completion date
|
BCL2 (B-cell CLL/lymphoma 2)
|
rezetamig (JNJ-8780)